News

Do you want to help support student interns? Apply Now!

As students have shown great interest in the upcoming STEM2VA Summer Internship Program, we at VA Bio-Connect want to continue to invite employers to register as host sites for this great opportunity in providing experiential learning to those interested in the life sciences. With an application close date of Jan 31, 2022. There were over 1000 students interested, with over 350 submissions by the closing date. Students have shown interest in all regions across the Commonwealth of Virginia, with specific student interests in bioengineering (180), medical devices (194), and pharmaceuticals (210) respectively.

 

Currently, over 25 employers including; Atelerix Life Sciences Inc. (Charlottesville/Albemarle), ReAlta Life Sciences and LifeNet Health (Coastal VA), Athari Bio Sciences, Inc. and Polaris Genomics (Northern VA), Tympanogen (Richmond), CytoRecovery (Roanoke), and many others across Virginia have registered to host student interns. Employers are encouraged to register as application reviews have just begun and will continue to mid-March to ensure student award letters are presented to the 100 candidates by March 31, 2022. This extraordinary experience is great for the next generation of life science professionals. If you are interested in hosting a student intern, please register here to receive your link to begin reviewing applications.

Any questions you have before registering, please contact VA Bio-Connect Admin at vbcintern@vabio.org for assistance. We look forward to matching you with qualified candidates.

Recent News

04/19/2024

ivWatch prevents IV leakage events at Frimley Health

Frimley Health NHS Foundation Trust has found that 100% of IV leakage incidents were prevented by a proprietary patient monitoring system from ivWatch, which could potentially save patients the pain or discomfort of adverse IV events. The initial two-week phase of the study, which was published in the British Journal of Nursing, found that continuous

04/17/2024

U.S. Department of Health and Human Services Awards Kaléo with Contract to Develop Next Generation Organophosphate Nerve Agent Poisoning Countermeasure

Kaléo, a privately-held U.S. pharmaceutical company today announced their selection by the Biomedical Advanced Research and Development Authority (BARDA), part of Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to develop the latest generation pralidoxime chloride auto-injector as a countermeasure against organophosphate or nerve agent poisoning.

04/15/2024

Activation Capital Welcomes Dr. Jim Pannucci as its Vice President of Entrepreneurship

Activation Capital, an innovation ecosystem development organization, announced today that it has appointed Jim Pannucci, Ph.D., PMP as its Vice President of Entrepreneurship. As the new Vice President of Entrepreneurship, Dr. Pannucci will help Activation Capital continue to grow a deep talent base of life sciences entrepreneurs operating in the region and help empower them